INOVIO PHARMACEUTICALS, INC. short interest in 2024
In 2024, INOVIO PHARMACEUTICALS, INC.'s disclosed short interest ran from 8.25% of shares outstanding on 12 Jan 2024 to 16.63% on 31 Dec 2024, a change of +8.38 percentage points. The year's high was 17.18% on 13 Dec 2024 and its low 8.00% on 31 May 2024, averaging 11.37% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 15.44 days on 31 Oct 2024. Full history: INOVIO PHARMACEUTICALS, INC..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 8.25% (12 Jan 2024)
- End of year
- 16.63% (31 Dec 2024)
- Change
- +8.38 pp
- High
- 17.18% (13 Dec 2024)
- Low
- 8.00% (31 May 2024)
- Average
- 11.37%
- Highest days to cover
- 15.44 (31 Oct 2024)
- SEC filings marked
- 7
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 8.25% | 2.33 | |
| 15 Mar 2024 | 8.81% | 2.87 | 10-K filed |
| 28 Mar 2024 | 9.00% | 4.53 | |
| 15 Apr 2024 | 9.68% | 6.22 | |
| 30 Apr 2024 | 8.68% | 5.78 | |
| 15 May 2024 | 9.14% | 6.72 | 10-Q filed, results (8-K) |
| 31 May 2024 | 8.00% | 5.60 | |
| 14 Jun 2024 | 8.01% | 9.03 | |
| 28 Jun 2024 | 8.71% | 2.90 | |
| 15 Jul 2024 | 11.99% | 7.03 | |
| 31 Jul 2024 | 11.49% | 7.83 | |
| 15 Aug 2024 | 11.25% | 9.97 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 11.56% | 11.41 | |
| 13 Sep 2024 | 11.75% | 13.54 | |
| 30 Sep 2024 | 12.87% | 9.76 | |
| 15 Oct 2024 | 13.39% | 8.79 | |
| 31 Oct 2024 | 13.50% | 15.44 | |
| 15 Nov 2024 | 14.38% | 9.43 | 10-Q filed, results (8-K) |
| 29 Nov 2024 | 14.48% | 8.57 | |
| 13 Dec 2024 | 17.18% | 3.08 | |
| 31 Dec 2024 | 16.63% | 3.29 |
See also: INOVIO PHARMACEUTICALS, INC.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.